Novel incretin-based therapy, such as mono, dual, and triple receptor agonists, may have merit in reducing the burden of steatotic liver disease (35), specifically those agents incorporating glucagon agonism, such as retatrutide, due to the direct hepatic activity of glucagon (36). This evidence concerns the gene GCG and liver disorder.